Jump to main content
Jump to site search

Issue 2, 2019
Previous Article Next Article

DePEGylation strategies to increase cancer nanomedicine efficacy

Author affiliations

Abstract

To maximize drug targeting to solid tumors, cancer nanomedicines with prolonged circulation times are required. To this end, poly(ethylene glycol) (PEG) has been widely used as a steric shield of nanomedicine surfaces to minimize serum protein absorption (opsonisation) and subsequent recognition and clearance by cells of the mononuclear phagocyte system (MPS). However, PEG also inhibits interactions of nanomedicines with target cancer cells, limiting the effective drug dose that can be reached within the target tumor. To overcome this dilemma, nanomedicines with stimuli-responsive cleavable PEG functionality have been developed. These benefit from both long circulation lifetimes en route to the targeted tumor as well as efficient drug delivery to target cancer cells. In this review, various stimuli-responsive strategies to dePEGylate nanomedicines within the tumor microenvironment will be critically reviewed.

Graphical abstract: DePEGylation strategies to increase cancer nanomedicine efficacy

Back to tab navigation

Article information


Submitted
14 Nov 2018
Accepted
03 Dec 2018
First published
04 Dec 2018

Nanoscale Horiz., 2019,4, 378-387
Article type
Minireview

DePEGylation strategies to increase cancer nanomedicine efficacy

L. Kong, F. Campbell and A. Kros, Nanoscale Horiz., 2019, 4, 378
DOI: 10.1039/C8NH00417J

Social activity

Search articles by author

Spotlight

Advertisements